CL2021000008A1 - Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) - Google Patents
Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)Info
- Publication number
- CL2021000008A1 CL2021000008A1 CL2021000008A CL2021000008A CL2021000008A1 CL 2021000008 A1 CL2021000008 A1 CL 2021000008A1 CL 2021000008 A CL2021000008 A CL 2021000008A CL 2021000008 A CL2021000008 A CL 2021000008A CL 2021000008 A1 CL2021000008 A1 CL 2021000008A1
- Authority
- CL
- Chile
- Prior art keywords
- heparinoid
- cancer treatment
- divisional application
- divisional
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644556P | 2012-05-09 | 2012-05-09 | |
US201261644623P | 2012-05-09 | 2012-05-09 | |
US201261648043P | 2012-05-16 | 2012-05-16 | |
US201261653362P | 2012-05-30 | 2012-05-30 | |
US201261664611P | 2012-06-26 | 2012-06-26 | |
US201261668709P | 2012-07-06 | 2012-07-06 | |
US201261678053P | 2012-07-31 | 2012-07-31 | |
US201261702207P | 2012-09-17 | 2012-09-17 | |
US201261724836P | 2012-11-09 | 2012-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000008A1 true CL2021000008A1 (es) | 2021-06-11 |
Family
ID=49549076
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014003017A CL2014003017A1 (es) | 2012-05-09 | 2014-11-07 | Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo |
CL2021000008A CL2021000008A1 (es) | 2012-05-09 | 2021-01-04 | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014003017A CL2014003017A1 (es) | 2012-05-09 | 2014-11-07 | Uso de un heparinoide interactuando con pf4 para tratar efecto mielodepresivo |
Country Status (21)
Country | Link |
---|---|
US (6) | US9271999B2 (es) |
EP (2) | EP3785720A1 (es) |
JP (3) | JP6177885B2 (es) |
KR (2) | KR102165348B1 (es) |
CN (3) | CN104411316B (es) |
AU (1) | AU2013260101B2 (es) |
BR (1) | BR112014028094B1 (es) |
CA (2) | CA2872855C (es) |
CL (2) | CL2014003017A1 (es) |
DK (1) | DK2846809T3 (es) |
EA (1) | EA029382B1 (es) |
ES (1) | ES2848050T3 (es) |
HK (1) | HK1207574A1 (es) |
HU (1) | HUE053247T2 (es) |
IL (1) | IL235593B (es) |
LT (1) | LT2846809T (es) |
MX (2) | MX370567B (es) |
PL (1) | PL2846809T3 (es) |
PT (1) | PT2846809T (es) |
SG (3) | SG11201407340YA (es) |
WO (1) | WO2013169355A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6177885B2 (ja) | 2012-05-09 | 2017-08-09 | カンテックス ファーマシューティカルズ, インコーポレイテッド | 骨髄抑制の処置 |
WO2015061358A1 (en) * | 2013-10-22 | 2015-04-30 | Cantex Pharmaceuticals, Inc. | Methods of treating and preventing radiation damage |
US20170096549A1 (en) | 2014-03-17 | 2017-04-06 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
US10052346B2 (en) | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
MX2017011374A (es) | 2015-03-06 | 2018-01-23 | Beyondspring Pharmaceuticals Inc | Método de tratamiento de cáncer asociado con una mutación de ras. |
CN109516981B (zh) | 2015-07-13 | 2019-10-22 | 大连万春布林医药有限公司 | 普那布林组合物 |
KR20180105685A (ko) | 2016-02-08 | 2018-09-28 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 투카레솔 또는 이의 유사체를 함유하는 조성물 |
KR20190015361A (ko) | 2016-06-06 | 2019-02-13 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증을 줄이는 조성물 및 방법 |
JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
CA3052190A1 (en) | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Method of reducing neutropenia |
CN107569486A (zh) * | 2017-08-23 | 2018-01-12 | 北京京佑奇康生物科技有限公司 | 孟鲁司特钠治疗血小板减少症的新用途 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
CA3089226A1 (en) * | 2018-01-24 | 2019-08-01 | Beyondspring Pharmaceuticals, Inc. | Composition and method for reducing thrombocytopenia via the administration of plinabulin |
US11874276B2 (en) | 2018-04-05 | 2024-01-16 | Dana-Farber Cancer Institute, Inc. | STING levels as a biomarker for cancer immunotherapy |
WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
CN113660943A (zh) * | 2019-01-25 | 2021-11-16 | 詹森药业有限公司 | 增强对全身放射/化学暴露反应的对器官和血管损伤的保护、造血恢复以及存活的方法 |
KR20220009955A (ko) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈에 의한 우울증 및 기타 다양한 장애의 치료 |
US20220305048A1 (en) * | 2019-08-26 | 2022-09-29 | Dana-Farber Cancer Institute, Inc. | Use of heparin to promote type 1 interferon signaling |
TW202128617A (zh) * | 2019-11-13 | 2021-08-01 | 日商大鵬藥品工業股份有限公司 | 三苯化合物之新穎鹽類 |
WO2021207697A1 (en) | 2020-04-10 | 2021-10-14 | Cantex Pharmaceuticals, Inc. | Treatment of acute lung injury |
KR20230058289A (ko) | 2021-10-21 | 2023-05-03 | 숙명여자대학교산학협력단 | 혈액암 치료를 위한 글리세오플빈 병용요법 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
US5804374A (en) | 1980-12-05 | 1998-09-08 | Massachusetts Insti. Technology | Nuclear factors associates with transcriptional regulation |
FR2553287B1 (fr) | 1983-10-18 | 1986-09-12 | Choay Sa | Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire |
DE3422518A1 (de) | 1984-06-16 | 1985-12-19 | B. Braun Melsungen Ag, 3508 Melsungen | Heparin-derivate, verfahren zu ihrer herstellung, diese enthaltende arzneimittel und ihre verwendung bei der behandlung von fettstoffwechselstoerungen |
FR2584606A1 (fr) | 1985-07-12 | 1987-01-16 | Dropic | Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif |
US5380716A (en) | 1988-12-15 | 1995-01-10 | Glycomed, Inc. | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation |
IT1234826B (it) | 1989-01-30 | 1992-05-29 | Alfa Wassermann Spa | Derivati eparinici e procedimento per la loro preparazione |
US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
AU7681091A (en) | 1990-04-05 | 1991-10-30 | John R Hoidal | Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases |
US5250519A (en) | 1991-03-29 | 1993-10-05 | Glycomed Incorporated | Non-anticoagulant heparin derivatives |
IT1254216B (it) | 1992-02-25 | 1995-09-14 | Opocrin Spa | Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
AU3938093A (en) | 1992-04-02 | 1993-11-08 | Baker Norton Pharmaceuticals, Inc. | Method and composition for treating antigen-induced and exercise-induced asthma |
US5668118A (en) | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
US5306724A (en) | 1992-08-17 | 1994-04-26 | Clintec Nutrition Company | Method for preventing and treating atherosclerosis |
GB2270841A (en) | 1992-09-09 | 1994-03-30 | Merck & Co Inc | Compositions for Treating vascular restenosis |
US5296471A (en) | 1992-12-22 | 1994-03-22 | Glycomed Incorporated | Method for controlling o-desulfation of heparin and compositions produced thereby |
US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
WO1994018989A1 (en) | 1993-02-22 | 1994-09-01 | Cavalier Pharmaceuticals, Inc. | Use of heparin to inhibit interleukin-8 |
SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
US5994318A (en) | 1993-10-04 | 1999-11-30 | Albany Medical College | Cochleate delivery vehicles |
US5840707A (en) | 1993-10-04 | 1998-11-24 | Albany Medical College | Stabilizing and delivery means of biological molecules |
AU2435795A (en) | 1994-05-06 | 1995-11-29 | Glycomed Incorporated | O-desulfated heparin derivatives, methods of making and uses thereof |
US5804560A (en) | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
US5990097A (en) | 1996-07-29 | 1999-11-23 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
US6154502A (en) | 1996-08-22 | 2000-11-28 | Intel Corporation | Signal constellation slicer |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
ATE240113T1 (de) | 1997-02-15 | 2003-05-15 | Millennium Pharm Inc | Behandlung von infarkten durch inhibierung von nf-kappab |
AU8657098A (en) | 1997-05-30 | 1998-12-30 | Arch Development Corporation | P-selectin translocation to vascular epithelial lumen by ionizing radiation |
US6406862B1 (en) | 1998-10-06 | 2002-06-18 | The United States Of America As Represented By The Secretary Of The Army | Dip-stick assay for C-reactive protein |
CN1326355A (zh) | 1998-11-13 | 2001-12-12 | 伊莱利利公司 | 治疗肝素诱导的血小板减少症的方法 |
US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
US6153217A (en) | 1999-01-22 | 2000-11-28 | Biodelivery Sciences, Inc. | Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents |
US6514502B1 (en) | 1999-01-26 | 2003-02-04 | Schering-Plough Veterinary Corporation | Propagation of bovine cononavirus in chinese hamster ovary cells |
WO2001019376A2 (en) | 1999-09-13 | 2001-03-22 | Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center | METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS |
US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
US20050026811A1 (en) | 2003-05-20 | 2005-02-03 | Mjalli Adnan M. M. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
WO2002083120A2 (en) * | 2001-04-18 | 2002-10-24 | Prometic Biosciences Inc. | Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors |
WO2003088980A1 (en) | 2002-04-18 | 2003-10-30 | Embury Stephen H | Method and composition for preventing pain in sickle cell patients |
JP2005535665A (ja) | 2002-07-09 | 2005-11-24 | ザ スクリプス リサーチ インスティテュート | 虚血および再灌流損傷を防止する方法 |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
WO2004050673A2 (en) | 2002-11-27 | 2004-06-17 | Massachusetts Institute Of Technology | Methods for synthesizing polysaccharides |
US20040180812A1 (en) | 2002-12-13 | 2004-09-16 | Technology Center | Methods of treating and preventing proliferative disease |
WO2005089365A2 (en) | 2004-03-16 | 2005-09-29 | The General Hospital Corporation | Treatment and prevention of abnormal cellular proliferation |
WO2005102359A1 (en) * | 2004-04-22 | 2005-11-03 | Celator Pharmaceuticals, Inc. | Liposomal formulations of anthracycline agents and cytidine analogs |
US20050261241A1 (en) | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
US7468358B2 (en) | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
US20050282775A1 (en) | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
US20060040896A1 (en) | 2004-08-18 | 2006-02-23 | Paringenix, Inc. | Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity |
JP2006076968A (ja) | 2004-09-10 | 2006-03-23 | Seikagaku Kogyo Co Ltd | 生理活性分子含有架橋ヘパリンゲル組成物 |
CN101583273A (zh) | 2005-07-22 | 2009-11-18 | 加利福尼亚大学董事会 | 肝素组合物和选择素抑制 |
WO2007019554A2 (en) | 2005-08-08 | 2007-02-15 | Momenta Pharmaceuticals, Inc. | Polysaccharides for delivery of active agents |
EP1939278A4 (en) | 2005-09-30 | 2009-06-03 | Takara Bio Inc | METHOD FOR PRODUCING A T CELL POPULATION |
KR20080080641A (ko) | 2005-12-16 | 2008-09-04 | 디엔피 캐나다 인코포레이티드 | 고지혈증용 키틴 유도체 |
WO2007115372A1 (en) | 2006-04-10 | 2007-10-18 | Monash University | A method of modulating beta-amyloid peptide production |
EP2043662B1 (en) | 2006-07-26 | 2015-09-09 | Intrexon Corporation | Methods and compositions for treating disease |
AU2007342338A1 (en) | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies |
US20090054374A1 (en) | 2007-02-28 | 2009-02-26 | Paringenix, Inc. | Methods of treating acute exacerbations of chronic obstructive pulmonary disease |
PT2155188E (pt) * | 2007-06-01 | 2013-12-19 | Abraxis Bioscience Llc | Métodos e composições para o tratamento de cancro recorrente |
WO2009015183A1 (en) | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
US8569262B2 (en) | 2007-11-02 | 2013-10-29 | Momenta Pharmaceuticals, Inc. | Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization |
WO2009117677A2 (en) | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
MX2010010904A (es) | 2008-04-04 | 2010-11-04 | Univ Utah Res Found | Eteres de glicosaminoglicosano semisinteticos alquilados, y metodos para elaborarlos y usarlos. |
US8476249B2 (en) * | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
WO2011038901A1 (en) | 2009-09-29 | 2011-04-07 | Activaero Gmbh | Improved method for treatment of patients with cystic fibrosis |
WO2011109877A1 (en) | 2010-03-12 | 2011-09-15 | The Australian National University | Heparan sulfate replacement therapy |
KR101570404B1 (ko) | 2010-03-24 | 2015-11-20 | 르 라보레또레 쎄르비에르 | 결장직장암 및 위창자암의 예방 |
JP2013531012A (ja) | 2010-06-28 | 2013-08-01 | ステムテック インターナショナル, インコーポレイテッド | 幹細胞の移動を増強するための方法および組成物 |
MX2013006020A (es) * | 2011-01-31 | 2013-10-01 | Celgene Corp | Composicion farmaceutica de analogos de citidina y metodos para su uso. |
WO2012106379A1 (en) * | 2011-02-01 | 2012-08-09 | Paringenix, Inc. | Sensitization of cancer cells to treatment |
WO2013016181A1 (en) | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
BR112014027333A2 (pt) | 2012-05-01 | 2017-07-18 | Univ Duke | composição, métodos de tratamento ou melhora, de prevenção, e, de diagnóstico de uma condição prejudicial que está associada com o teor elevado de sulfato de heparano em um indivíduo que foi o receptor de um órgão, tecido ou células transplantados |
JP6177885B2 (ja) | 2012-05-09 | 2017-08-09 | カンテックス ファーマシューティカルズ, インコーポレイテッド | 骨髄抑制の処置 |
SG10201706858XA (en) | 2013-02-28 | 2017-09-28 | Harvard College | Methods and compositions for mobilizing stem cells |
WO2015061358A1 (en) | 2013-10-22 | 2015-04-30 | Cantex Pharmaceuticals, Inc. | Methods of treating and preventing radiation damage |
US20160296552A1 (en) | 2013-10-24 | 2016-10-13 | Cantex Pharmaceuticals, Inc. | Treating Bacterial Infections of the Lung |
US20170096549A1 (en) | 2014-03-17 | 2017-04-06 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
US10052346B2 (en) * | 2015-02-17 | 2018-08-21 | Cantex Pharmaceuticals, Inc. | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids |
WO2016133907A1 (en) | 2015-02-17 | 2016-08-25 | Cantex Pharmaceuticals, Inc. | Adoptive cell transfer methods |
US20170106011A1 (en) | 2015-10-20 | 2017-04-20 | Cantex Pharmaceuticals, Inc. | Methods of treating traumatic brain injury and sequelae |
WO2017123549A1 (en) | 2016-01-11 | 2017-07-20 | Cantex Pharmaceuticals, Inc. | Methods of treating or preventing graft-versus-host disease using hmgb1-interacting heparinoids |
-
2013
- 2013-03-13 JP JP2015511452A patent/JP6177885B2/ja not_active Expired - Fee Related
- 2013-03-13 US US13/801,990 patent/US9271999B2/en not_active Expired - Fee Related
- 2013-03-13 EP EP20189050.6A patent/EP3785720A1/en not_active Withdrawn
- 2013-03-13 KR KR1020147034512A patent/KR102165348B1/ko active IP Right Grant
- 2013-03-13 ES ES13787651T patent/ES2848050T3/es active Active
- 2013-03-13 PT PT137876512T patent/PT2846809T/pt unknown
- 2013-03-13 HU HUE13787651A patent/HUE053247T2/hu unknown
- 2013-03-13 WO PCT/US2013/031053 patent/WO2013169355A1/en active Application Filing
- 2013-03-13 LT LTEP13787651.2T patent/LT2846809T/lt unknown
- 2013-03-13 AU AU2013260101A patent/AU2013260101B2/en not_active Ceased
- 2013-03-13 EA EA201492052A patent/EA029382B1/ru not_active IP Right Cessation
- 2013-03-13 EP EP13787651.2A patent/EP2846809B1/en active Active
- 2013-03-13 SG SG11201407340YA patent/SG11201407340YA/en unknown
- 2013-03-13 CN CN201380036055.1A patent/CN104411316B/zh not_active Expired - Fee Related
- 2013-03-13 CA CA2872855A patent/CA2872855C/en active Active
- 2013-03-13 SG SG10201914117QA patent/SG10201914117QA/en unknown
- 2013-03-13 MX MX2014013633A patent/MX370567B/es active IP Right Grant
- 2013-03-13 CN CN202110756600.0A patent/CN113521093A/zh active Pending
- 2013-03-13 CA CA3122808A patent/CA3122808A1/en not_active Abandoned
- 2013-03-13 SG SG10201603059YA patent/SG10201603059YA/en unknown
- 2013-03-13 DK DK13787651.2T patent/DK2846809T3/da active
- 2013-03-13 CN CN201810295102.9A patent/CN108498532B/zh not_active Expired - Fee Related
- 2013-03-13 BR BR112014028094-0A patent/BR112014028094B1/pt not_active IP Right Cessation
- 2013-03-13 KR KR1020207028539A patent/KR102452803B1/ko active IP Right Grant
- 2013-03-13 PL PL13787651T patent/PL2846809T3/pl unknown
- 2013-08-09 US US13/963,526 patent/US8734804B2/en active Active
-
2014
- 2014-11-07 CL CL2014003017A patent/CL2014003017A1/es unknown
- 2014-11-07 MX MX2019009437A patent/MX2019009437A/es unknown
- 2014-11-09 IL IL235593A patent/IL235593B/en active IP Right Grant
-
2015
- 2015-08-25 HK HK15108246.8A patent/HK1207574A1/xx unknown
-
2016
- 2016-01-20 US US15/001,773 patent/US20160213706A1/en not_active Abandoned
-
2017
- 2017-03-21 JP JP2017054390A patent/JP6448694B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-16 US US15/923,470 patent/US20180296590A1/en not_active Abandoned
- 2018-10-01 JP JP2018186702A patent/JP6726252B2/ja not_active Expired - Fee Related
-
2019
- 2019-08-15 US US16/541,660 patent/US11229664B2/en active Active
-
2021
- 2021-01-04 CL CL2021000008A patent/CL2021000008A1/es unknown
- 2021-12-14 US US17/550,942 patent/US20220354882A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000008A1 (es) | Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017) | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2017003024A1 (es) | Tratamiento para el cancer a traves de la manipulación de microflora comensal | |
NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2015000711A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona como inhibidores de notch; composicion farmaceutica y uso en el tratamiento del cancer. | |
EA201400178A1 (ru) | Лечение рака молочной железы | |
CL2015000873A1 (es) | Métodos para el tratamiento del síndrome de alport. | |
UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
BR112015011112A2 (pt) | composto oligomérico, oligômero, composição farmacêutica, uso do composto oligomérico, método de síntese de um composto oligomérico e método de tratamento de uma doença. | |
CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. | |
UY34566A (es) | 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
ES2765949T8 (es) | Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer | |
CO7020879A2 (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca | |
ES2969659T3 (es) | Sistemas para el tratamiento de infecciones pulmonares | |
CL2015002591A1 (es) | Entidades químicas. | |
ES2897914T8 (es) | Compuestos que contienen nitrógeno, adecuados para el uso en la producción de poliuretanos | |
BR112014005091A2 (pt) | composição farmacêutica para o tratamento do câncer compreendendo conjugado de interferon alfa | |
BR112014030416A2 (pt) | composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção. | |
CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. |